Fig. 2.

Proportions of patients receiving tofacitinib monotherapy or combination therapy at 90 days post-index for patients with PsA initiating tofacitinib. csDMARD conventional synthetic disease-modifying antirheumatic drug, N number of patients in each cohort, n number of patients in each category, PsA psoriatic arthritis. ^aOther possible combination therapies included auranofin, aurothioglucose, azathioprine, chloroquine, cyclophosphamide, cyclosporine, gold sodium thiomalate, minocycline, penicillamine, tacrolimus, and thalidomide